Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-07-08
2009-11-10
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07615527
ABSTRACT:
Peptide fragments that modulate thrombosis and methods of use thereof are provided. Also provided are synthetic bioactive anti-coagulation peptides, compositions comprising such peptides and methods for the administration to patients in need thereof.
REFERENCES:
patent: 4346078 (1982-08-01), Bajusz et al.
patent: 5457090 (1995-10-01), Scott et al.
patent: 5705606 (1998-01-01), Charo et al.
patent: 5858350 (1999-01-01), Vournakis et al.
patent: 2002/0119572 (2002-08-01), Jacobson et al.
patent: WO 98/12318 (1998-03-01), None
Rixon et al. Biochemistry 24: 2077-2086 (1985).
Farrell et al., “Recombinant Human Fibrinogen and Sulfation of the Gamma' Chain”, Biochemistry 30: 9414-9420 (1991).
Collet, J.P., et al., “Influence of γ' Fibrinogen Splice Variant on Fibrin Physical Properties and Fibrinolysis Rate”, Arterioscler. Throm. Vasc. Biol., vol. 24: p. 1-6 (2004).
Farrell, D.H., “Pathophysiologic roles of fibrinogen gamma chain”, Current Opinion in Hematology, vol. 11: pp. 151-155.
Lovely, R.S., et al., “Fibrinogen γ' chain binds thrombin exosite II”, J. of Thrombosis and Haemostasis, vol. 1: 124-131, (2002).
Pospisil, C.H., et al., “Evidence That Both Exosites on Thrombin Participate in Its High Affinity Interaction with Fibrin”, J. of Biol. Chem., vol. 278: pp. 21584-21591 (2003).
Cooper, A.V., et al., “Fibrinogen gamma-chain splice varient γ' alters fibrin formation and structure”, Blood, vol. 102, pp. 535-540, (2003).
Podor, T.J., et al., “Incorporation of Vitronectin into Fibrin Clots”, J. of Biol. Chem., vol. 277: pp. 7520-7528, (2002).
Lovely, R.S., et al., “Association of γA/γ' Fibrinogen Levels and Coronary Artery Disease”, Thromb. Haemost., vol. 88: pp. 26-31, (2002).
De Bosch, N.B., et al., “Inhibition of Thrombin Generation in Plasma by Fibrin Formation (Antithrombin I)”, Thromb. Haemost., vol. 88: 253-8, (2002).
Meh, D.A., et al., “The Amino Acid Sequence in Fibrin Responsible for High Affinity Thrombin Binding”, Thromb. Haemost., vol. 85: 470-4, (2001).
Dallabrida, S.M., et al., “Factor XIIIa supports microvascular endothelial cell adhesion and inhibits capillary tube formation in fibrin”, Blood, vol. 95: pp. 2586-2592, (2000).
Moaddel, M., et al., “The Role of γA/γ' Fibrinogen in Plasma Factor XIII Activation”, J. of Biological Chemistry, vol. 275: pp. 32135-32140, (2000).
Moaddel, M., et al., “Interactions of Human Fibrinogens with Factor XIII: Roles of Calcium and the γ' Peptide”, Biochemistry, vol. 39: pp. 6698-6705, (2000).
Falls, L.A., et al., “Resistance of γA/γ' Fibrin Clots to Fibrinolysis”, J. of Biological Chemistry, vol. 272: pp. 14251-14256, (1997).
Siebenlist, K.R., et al., “Plasma Factor XIII Binds Specifically to Fibrinogen Molecules Containing γ' Chains”, Biochemistry, vol. 35: pp. 10448-10453, (1996).
Meh, D.A., et al., “Identification and Characterization of the Thrombin Binding Sites on Fibrin”, J. of Biological Chemistry, vol. 271: pp. 32121-32125, (1996).
Hofsteenge, J. “The effect of substituting phosphotyrosine for sulphtyrosine on the activity of hirudin”; Eur. J. Biochem., 188: 55-59(1990).
Hortin, G.L., et al., “Inhibition of thrombin's clotting activity by synthetic peptide segments of its inhibitors and substrates,” Biochem. Biophys. Res. Comm., 169(2):437-442, (Jun. 15, 1990).
Farrell, D.H., “Pathophysiologic roles of fibrinogen gamma chain”, Current Opinion in Hematology, vol. 11: pp. 151-155, 2004.
Farrell David H.
Lovely Rehana S.
Dann Dorfman Herrell & Skillman
Desai Anand U
Netter, Jr. Robert C.
Oregon Health & Science University
Rigaut Kathleen D.
LandOfFree
Peptides which modulate blood coagulation and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides which modulate blood coagulation and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides which modulate blood coagulation and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4062143